Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853805 | 0.90 | BRAF (0.65) | BRAFCYP2C9 | |
| SCHEMBL2851503 | 0.90 | BRAF (0.61) | BRAFCYP2C9 | |
| SCHEMBL2853201 | 0.90 | BRAF (0.57) | BRAFCYP2C9 | |
| SCHEMBL2853431 | 0.89 | BRAF (0.56) | BRAFCYP2C9 | |
| SCHEMBL2849315 | 0.88 | BRAF (0.55) | BRAFCYP2C9 | |
| SCHEMBL2854041 | 0.87 | BRAF (0.54) | BRAFCYP2C9 | |
| SCHEMBL2851320 | 0.86 | BRAF (0.60) | BRAFCYP2C9 | |
| SCHEMBL2853965 | 0.84 | BRAF (0.48) | BRAFCYP2C9 | |
| SCHEMBL2857370 | 0.79 | BRAF (0.48) | BRAFCYP2C9 | |
| SCHEMBL826173 | 0.79 | BRAF (0.56) | BRAFCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0555742-B1 | Process for the preparation of fluorchlorhydrocarbon-free flexible polyurethane foams using urethane groups containing polyisocyanate blends based on diphenylmethane-diisocyanate as well as likewise modified polyisocyanate blends | BASF AG (DE) | 1998-05-06 | — | — | EP | claimed |
| EP-0538673-B1 | Clear, vapour-sterilisable, non-zytotoxic, essentially compact polyurethane casting compounds, process for their preparation and their use, especially for medical-technical articles | BASF AG (DE) | 1998-01-07 | — | — | EP | claimed |
| EP-0555742-A2 | Process for the preparation of fluorchlorhydrocarbon-free flexible polyurethane foams using urethane groups containing polyisocyanate blends based on diphenylmethane-diisocyanate as well as likewise modified polyisocyanate blends | BASF Aktiengesellschaft (DE) | 1993-08-18 | — | — | EP | claimed |
| EP-0538673-A2 | Clear, vapour-sterilisable, non-zytotoxic, essentially compact polyurethane casting compounds, process for their preparation and their use, especially for medical-technical articles | BASF Aktiengesellschaft (DE) | 1993-04-28 | — | — | EP | claimed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-0708127-B2 | Process for the preparation of rigid polyurethane foams having reduced thermal conductivity | BASF POLYURETHANES GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-0952169-B1 | Process for the preparation of polyurethane rigid foams with reduced heat conductivity and their use | BASF AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| EP-1088841-B1 | Polyurethane embedding compositions, in particular for items for medical engineering | BASF AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| EP-1088840-B1 | Clear, steam-sterilisable, non-cytotoxic polyurethane casting compostitions, process for their preparation and their use, especially for medical-technical articles | BASF AG (DE) | 2004-12-15 | — | — | EP | disclosed |
| EP-0280354-A1 | UV irradiation system and process for developing it | den Dekker, Gerardus Matthijs (NL) | 1988-08-31 | — | — | EP | disclosed |
| EP-0262378-A2 | Process for the production of elastic essentially compact polyurethane mouldings with improved mould release properties | BASF Aktiengesellschaft (DE) | 1988-04-06 | — | — | EP | disclosed |
| EP-0260685-A1 | Internal mould release agents, their use in the preparation of moulded pieces according to the polyisocyanate-polyaddition process, and process for the preparation of moulded pieces | BASF Aktiengesellschaft (DE) | 1988-03-23 | — | — | EP | disclosed |
| EP-0254177-A2 | Moisture-curable, storage-stable one-component polyurethane systems and their use | BASF Aktiengesellschaft (DE) | 1988-01-27 | — | — | EP | disclosed |
| EP-0218175-A2 | Process for the preparation of cellular or compact polyurethane-polyurea moulded parts with mould release properties, as well as internal mould release agents and their use in the polyisocyanate-polyaddition process | BASF Aktiengesellschaft (DE) | 1987-04-15 | — | — | EP | disclosed |
| EP-0111121-B1 | LIQUID POLYSOCYANATE MIXTURES CONTAINING URETHANE GROUPS ON THE BASIS OF DIPHENYLMETHANE DIISOCYANATE, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE IN THE PREPARATION OF FLEXIBLE POLYURETHANE FOAMS | BASF Aktiengesellschaft (DE) | 1986-08-06 | — | — | EP | disclosed |
| EP-0124071-A2 | Process for the production of elastic, compact or cellular polyurethanes | BASF Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
| EP-0111121-A1 | Liquid polysocyanate mixtures containing urethane groups on the basis of diphenylmethane diisocyanate, process for the preparation thereof and their use in the preparation of flexible polyurethane foams | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885CYP2C9 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.